Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study
文献类型：期刊论文
| 作者 | Wu, Y. -L.11; Zhou, Q.12; Chen, M.13; Pan, Y.11; Jian, O.14; Hu, D.15; Lin, Q.16; Wu, G.17; Cui, J.18; Chang, J.3 |
| 刊名 | JOURNAL OF THORACIC ONCOLOGY
 |
| 出版日期 | 2022-09-01 |
| 卷号 | 17 |
| ISSN号 | 1556-0864 |
| 关键词 | CCRT sCRT PD-L1 inhibitor |
| WOS研究方向 | Oncology ; Respiratory System |
| 语种 | 英语 |
| 出版者 | ELSEVIER SCIENCE INC |
| WOS记录号 | WOS:000858678100012 |
| 源URL | [http://ir.hfcas.ac.cn:8080/handle/334002/129843]  |
| 专题 | 中国科学院合肥物质科学研究院 |
| 作者单位 | 1.CStone Pharmaceut Suzhou Co Ltd, Shanghai, Peoples R China 2.Fujian Med Univ, Fujian Prov Canc Hosp, Fuzhou, Peoples R China 3.Fudan Univ, Canc Ctr, Shanghai, Peoples R China 4.Shandong Univ, Qilu Hosp, Jinan, Peoples R China 5.China Med Univ, Hosp 1, Shenyang, Peoples R China 6.Army Med Ctr PLA, Chongqing, Peoples R China 7.China Med Univ, Shengjing Hosp, Shenyang, Peoples R China 8.China Three Gorges Univ, Coll Clin Med Sci 1, Yichang Cent Peoples Hosp, Yichang, Peoples R China 9.Linyi Canc Hosp, Linyi, Peoples R China 10.Jiangxi Canc Hosp, Nanchang, Peoples R China |
| 推荐引用方式 GB/T 7714 | Wu, Y. -L.,Zhou, Q.,Chen, M.,et al. Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study[J]. JOURNAL OF THORACIC ONCOLOGY,2022,17. |
| APA | Wu, Y. -L..,Zhou, Q..,Chen, M..,Pan, Y..,Jian, O..,...&Yang, J..(2022).Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study.JOURNAL OF THORACIC ONCOLOGY,17. |
| MLA | Wu, Y. -L.,et al."Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study".JOURNAL OF THORACIC ONCOLOGY 17(2022). |
入库方式： OAI收割
来源：合肥物质科学研究院
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。